Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530–8.
Article CAS PubMed Google Scholar
Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur SC. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2022;14(4):CD011412.
US Food and Drug Administration. Keppra prescribing information. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021035s104,021505s044lbl.(pdf. Accessed 25 Jun 2023.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.
Article CAS PubMed Google Scholar
Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:907197.
Article CAS PubMed PubMed Central Google Scholar
Perlman A, Wanounou M, Goldstein R, Choshen Cohen L, Singer DE, Muszkat M. Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS). CNS Drugs. 2019;33:1223–8.
Article CAS PubMed Google Scholar
Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of enzyme-inducing antiseizure medications on the risk of sub-therapeutic concentrations of direct oral anticoagulants: a retrospective cohort study. CNS Drugs. 2021;35:305–16.
Article CAS PubMed PubMed Central Google Scholar
Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110:1526–36.
Article CAS PubMed PubMed Central Google Scholar
Ip BY, Ko H, Wong GL, Yip TC, Lau LH, Lau AY, et al. Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis. CNS Drugs. 2022;36:1313–24.
Article CAS PubMed PubMed Central Google Scholar
Cohen H, Mahajna G, Ben-Shushan T, Matok I, Eyal S. The extent of cytochrome P450 3A induction by antiseizure medications: a systematic review and network meta-analysis. Epilepsia. 2024;65:445–55.
Article CAS PubMed Google Scholar
Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment. CNS Drugs. 2023;37:203–14.
Article CAS PubMed Google Scholar
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23:1612–76.
Lombardo L, Pellitteri R, Balazy M, Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res. 2008;5:82–92.
Article CAS PubMed Google Scholar
Moerman L, wyffels L, Slaets D, Raedt R, Boon P, De Vos F. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with 11C-desmethylloperamide. Epilepsy Res. 2011;94:18–25.
Article CAS PubMed Google Scholar
Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46:93–9.
Article CAS PubMed Google Scholar
Abou Kaoud M, Nissan R, Segev A, Sabbag A, Orion D, Maor E. Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study. CNS Drugs. 2023;37:1111–21.
Article CAS PubMed Google Scholar
Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Fisher Negev T, Hochberg-Klein S, et al. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019;8:19.
Article PubMed PubMed Central Google Scholar
Gosselin RC, Funk (Adcock) DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med. 2014;138:1680–4.
Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban: an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183–7.
Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2:566.
Gosselin R, Adcock D, Bates S, Douxfils J, Favaloro E, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118:437–50.
DrugBank. Cytochrome P-450 CYP3A4 inducers. Available from: https://www.drugbank.ca/categories/DBCAT003896. Accessed 9 Jun 2020.
US Food and Drug Administration. For healthcare professionals: FDA’s examples of drugs that interact with CYP enzymes and transporter systems. 2023. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. Accessed 5 Mar 2024.
Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135:e604–33.
Article CAS PubMed PubMed Central Google Scholar
Mangiardi M, Iaccarino G, Alessiani M, Bonura A, Anticoli S. Treating post-stroke epilepsy in a patient with multiple comorbidities. Cureus. 2023;15: e38483.
PubMed PubMed Central Google Scholar
Brigo F, Lattanzi S, Zelano J, Bragazzi NL, Belcastro V, Nardone R, et al. Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: a systematic review with network meta-analysis. Seizure. 2018;61:57–62.
Article CAS PubMed Google Scholar
Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450–9.
Article CAS PubMed Google Scholar
Paciullo F, Costa C, Gresele P. Rivaroxaban plasma levels and levetiracetam: a case report. Ann Intern Med. 2020;173:71–2.
Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Sci Rep. 2023;13:9257.
Article CAS PubMed PubMed Central Google Scholar
Ranzato F, Roberti R, Deluca C, Carta M, Peretti A, Polo D, et al. Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective. Neurol Sci. 2024;45:277–88.
Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eu Heart J Cardiovasc Pharmacother. 2023;9:722–30.
Giustozzi M, Mazzetti M, Paciaroni M, Agnelli G, Becattini C, Vedovati MC. Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation. Clin Drug Investig. 2021;41:43–51.
Article CAS PubMed Google Scholar
Wang C-L, Wu VC-C, Chang K-H, Tu H-T, Kuo C-F, Huang Y-T, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6:147–54.
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021;21:208.
Article CAS PubMed PubMed Central Google Scholar
Chang C-S, Liao C-H, Lin C-C, Lane H-Y, Sung F-C, Kao C-H. Patients with epilepsy are at an increased risk of subsequent stroke: a population-based cohort study. Seizure. 2014;23:377–81.
Renoux C, Dell’Aniello S, Saarela O, Filion KB, Boivin J-F. Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study. BMJ Open. 2015;5: e008365.
Article PubMed PubMed Central Google Scholar
Redfors P, Holmegaard L, Pedersen A, Jern C, Malmgren K. Long-term follow-up of post-stroke epilepsy after ischemic stroke: room for improved epilepsy treatment. Seizure. 2020;76:50–5.
留言 (0)